anti-NY-ESO-1 T-cell receptor CD62L+ T cells

anti-NY-ESO-1 T-cell receptor CD62L+ T cells are an experimental autologous T-cell receptor (TCR) engineered T-cell therapy. The treatment involves harvesting a patient's own T cells and genetically engineering them to express a TCR specific for the New York esophageal squamous cell carcinoma 1 (NY-ESO-1) antigen, a cancer-testis antigen commonly expressed in various malignancies. A critical and distinguishing feature of this therapy is the enrichment or selection of CD62L (L-selectin) positive T cells during the manufacturing process. CD62L is a marker for naive and central memory T-cell populations, which are associated with superior proliferative capacity and long-term persistence in vivo compared to more differentiated effector T cells. By administering a product primarily composed of CD62L+ memory-like cells, the therapy aims to enhance the durability of the anti-tumor response and improve outcomes in patients with NY-ESO-1-positive solid tumors, such as synovial sarcoma, melanoma, and myxoid/round cell liposarcoma.

Other names

CD62L-enriched anti-NY-ESO-1 TCR T cellsCD-62L-enriched anti-NY-ESO-1 TCR T cellsCD 62L-enriched anti-NY-ESO-1 TCR T cellsL-selectin-enriched NY-ESO-1 TCR T cellsanti-NY-ESO-1 TCR CD62L+ T cells